ImmunityBio, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDImmunityBio, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings growth of 41% provides fundamental context to the price action. However, price is extended 88% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $7.55 | +29.53% | ABOVE |
| 50 SMA | $5.21 | +87.57% | ABOVE |
| 100 SMA | $3.75 | +160.97% | ABOVE |
| 150 SMA | $3.33 | +193.65% | ABOVE |
| 200 SMA | $3.20 | +205.53% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IBRX in an uptrend right now?
IBRX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, IBRX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is IBRX overbought or oversold?
IBRX's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is IBRX outperforming the market?
IBRX has a Relative Strength (RS) Rating of 98 out of 99. Yes, IBRX is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is IBRX in its 52-week range?
IBRX is trading at $9.78, which is 79% of its 52-week high ($12.43) and 75% above its 52-week low ($1.83).
How volatile is IBRX?
IBRX has a Beta of 1.39 and 52-week volatility of 106%. It's more volatile than the S&P 500 - expect bigger swings.